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Therapeutic concentrations of voriconazole in invasive fungal infections (IFIs) are ensured using a drug monitoring approach, which relies on attainment of steady-state pharmacokinetics. For voriconazole, time to reach steady state can vary from 5-7 days, not optimal for critically ill patients. We developed a population pharmacokinetic/pharmacodynamic model-based approach to predict doses that can maximize the net benefit (probability of efficacy-probability of adverse events) and ensure therapeutic concentrations, early on during treatment. The label-recommended 200 mg voriconazole dose resulted in attainment of targeted concentrations in 80% patients in the case of Candida spp. infections, as compared to only 40-50% patients, with net benefit ranging from 5.8-61.8%, in the case of Aspergillus spp. infections. Voriconazole doses of 300-600 mg were found to maximize the net benefit up to 51-66.7%, depending on the clinical phenotype (due to CYP2C19 status and pantoprazole use) of the patient and type of Aspergillus infection.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE SUBJECT? þ Voriconazole shows a significant interindividual variability in clinical response. Therapeutic drug monitoring is used to ensure therapeutic concentrations in clinic.
WHAT QUESTION DID THIS STUDY ADDRESS?
þ This is the first model-based analysis aimed to optimize voriconazole doses, which can maximize the probability of achieving therapeutic concentrations, early on during the course of treatment. WHAT THIS STUDY ADDS TO OUR KNOWLEDGE þ Label-recommended 200 mg voriconazole dose was sufficient for the treatment of Candida spp. IFIs. However, voriconazole doses ranging from 300-600 mg were needed for the successful treatment of Aspergillus spp. IFIs, depending on the clinical phenotype of the patient and type of Aspergillus infection. HOW THIS MIGHT CHANGE CLINICAL PHARMA-COLOGY OR TRANSLATIONAL SCIENCE þ Our results can change the way voriconazole is dosed in patients suffering from invasive fungal infections. Proposed dosing recommendations can help clinicians to determine an optimal treatment strategy for a particular patient based on clinical phenotype and type of infection.
Invasive fungal infections (IFIs) are common in immunocompromised patients, such as those with solid organ transplant or bone marrow transplants. 1, 2 Voriconazole is a triazole, antifungal agent, used as a first-line agent for the treatment for IFIs, mainly caused by Aspergillus spp. It is also effective against Candida spp., 3, 4 although it is not a first-line agent for these fungal pathogens. According to the Infectious Diseases Society of America (IDSA) guidelines, 5 voriconazole should be dosed according to the patient's body weight (loading dose of 6 mg/kg intravenous (i.v.) infusion or 400 mg b.i.d. orally for 24 h, followed by a 4-mg/kg i.v. or 200-mg b.i.d. oral maintenance dose). In adults, voriconazole is metabolized by CYP450 enzymes, 6, 7 mainly by CYP2C19. Its CYP-mediated metabolism can be saturated at therapeutic concentrations, which contributes to the large interindividual variability in voriconazole exposure. To ensure therapeutic concentrations are reached clinically, therapeutic drug monitoring (TDM) is widely used. Using TDM, steadystate trough concentrations (C trough,ss ) are measured on day 5-7, and doses are adjusted if the C trough,ss is not within the therapeutic range of voriconazole (2-6 mg/L). 8 However, this waiting period of 5-7 days is particularly problematic in critically ill patients and is associated with high fatality rates. 2 In addition, genetic polymorphisms in CYP2C19, 9-11 drugdrug interactions, comorbidities, age, and weight affect the pharmacokinetics (PK) of voriconazole and further contribute to the large interindividual variability in voriconazole exposure.
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CYP2C19 polymorphisms account for 39% of the variability in clearance in healthy adults 10 following a single dose of voriconazole. We showed in a previous publication 8 that patients with *1/*17 (rapid metabolizers, RM) or *17/*17 (ultrarapid metabolizers, UM) CYP2C19 genotype have a higher prevalence of subtherapeutic concentrations compared to other CYP2C19 genotypes, such as *1/*1 (normal metabolizers, NM); *1/*2, *2/*17 (intermediate metabolizers, IM) and *2/*2 (poor metabolizers, PM), following the same mg/kg maintenance dose.
In isolation, information on voriconazole PK is of limited meaning because it does not consider the susceptibility of the infecting organism towards the drug. Therefore, both the PK of voriconazole and the associated pharmacodynamic (PD) response as well as differences therein (e.g., MIC distributions) need to be taken into consideration when attempting to establish the optimal voriconazole dosing regimen. The objective of this study was to establish the optimal dosing regimen for voriconazole against Candida spp. and Aspergillus spp. by accounting for clinically relevant sources of variability including CYP2C19 polymorphisms, drug-drug interactions, and MIC distributions of the infecting organisms.
RESULTS

Population pharmacokinetic analysis
A one-compartment body model with first-order absorption and Michaelis-Menten elimination described the clinical data reasonably well (Supplemental Figure S1 ). CYP2C19 genotype and pantoprazole use significantly affected the clearance of voriconazole, as highlighted in the exploratory analysis (see Methods). While there was no significant difference in clearance between NM and IM, maximum metabolic capacity (V max ) was 29% higher in RM/UM compared to NM and IM ( Table S1 ). The impact of drug-drug interactions was reflected in an increase in the Michaelis-Menten constant (K m ) values, which were estimated to be 79% higher in the presence of pantoprazole. We consequently decided to categorize our study subjects into four groups for further analysis: 1) NM/IM nonpantoprazole, 2) NM/IM pantoprazole, 3) RM/UM nonpantoprazole, and 4) RM/UM pantoprazole. Age, weight, sex, and comorbidities were not identified as significant covariates in our analysis. The estimated value for voriconazole's apparent volume of distribution (Figure 1b ) PK/PD index of efficacy yielded similar probability of target attainment (PTA) for all the phenotypes of voriconazole. For MIC 0.12 mg/L, all phenotypes showed 90% PTA, with insignificant differences among them (Figure 1b) . At MIC >0.12 mg/L, the PTA is lowest for RM/UM nonpantoprazole (Figure 1b) , while it is highest for NM/IM pantoprazole. For instance, at an MIC of 1 mg/L, 23.3% RM/UM nonpantoprazole, 39.9% NM/IM nonpantoprazole, 46.5% RM/UM pantoprazole, and 64.9% NM/IM pantoprazole patients achieved the target (Figure 1b) . PTA was lower in RM/UM compared to NM/IM patients in both pantoprazoleand nonpantoprazole use groups. Pantoprazole improved the PTA by 25%, for both RM/UM and NM/IM patients ( Figure 1b) . Overall, 43.6% of patients achieved the target, following 200 mg voriconazole dose at MIC of 1 mg/L, irrespective of the phenotype ( Figure 1b) . These probabilities are consistent with those predicted with a PK/PD index of C trough,ss >2 ( Table 1) .
Susceptibility of Candida spp. against voriconazole was higher than Aspergillus spp., as evident in MIC distributions ( Figure 5d ). Cumulative fraction of response (CFR) was 80% for most of the Candida spp., except C. krusei (Figure 1d ) while it was 40-70% for Aspergillus spp. (Figure 1c) , following a labelrecommended 200 mg oral voriconazole dose. The phenotypic differences were not as pronounced in the case of Candida spp. (Figure 1d ), unlike Aspergillus spp. (Figure 1c) , where CFR was highest for NM/IM pantoprazole, followed by RM/UM pantoprazole, NM/IM nonpantoprazole, and RM/UM nonpantoprazole phenotype. Figure S2 shows the respective CFR and safety (VAE) for all phenotypes and Aspergillus spp. with voriconazole dose. For A. fumigatus, the most frequent cause of Aspergillus spp. infections, the 200 mg dose resulted in a net benefit of only 27.8%, 43.5%, 52.9%, and 61.8% for RM/UM nonpantoprazole, NM/IM nonpantoprazole, RM/UM pantoprazole, and NM/IM pantoprazole phenotypes, respectively ( Figure 2) . At the proposed 500 mg, 400 mg, 400 mg, and 300 mg doses (Figure 3 ), the net benefit (Figures 2, 3) . Additional benefitrisk analysis revealed that the relationship of voriconazole dose with other adverse events (AEs), such as bilirubin elevation (Figure S3 ), aspartate aminotransferase (AST) or alkaline phosphatase (ALP) elevation, was shallow and did not affect dose selection. Based on our analysis, we have provided dosing recommendations for two main clinical scenarios: 1) reactive dose adjustment for existing/suspected infection ( Figure 4a ) and 2) prospective dose optimization for subjects undergoing "high-risk procedures," such as organ transplant surgery (Figure 4b) . In other words, we have distinguished between intent-to-treat and intent-to-prevent scenarios. In scenario 1 (Figure 4a ), patients infected with Candida spp. and Aspergillus spp. infections should be started on a standard loading dose and the susceptibility of fungal isolates to voriconazole tested. While label-recommended doses can be used prior to the availability of the susceptibility testing results, a further dosing regimen should take the pathogen's susceptibility to voriconazole into consideration. For Candida spp. infections, the label-recommended maintenance dose of 200 mg voriconazole should be sufficient for all patients. In contrast, voriconazole doses need to be increased for patients with Aspergillus spp. infections. The magnitude of this increase depends on the CYP2C19 genotype and coadministration of pantoprazole. A TDM approach should be adopted when the CYP2C19 genotype or susceptibility of infection is unknown. In scenario 2 (Figure 4b) , patients who are at risk for infections, such as those undergoing liver/bone marrow transplantation, should be genotyped for CYP2C19 a priori. If these patients are infected posttransplantation, the results from CYP2C19 genotyping can then be used to optimize steady-state exposure of voriconazole early on, depending on the susceptibility of the pathogen.
DISCUSSION
According to the FDA-approved label, 4 a maintenance dose of 4 mg/kg i.v or 200 mg oral b.i.d. should be sufficient to achieve therapeutic voriconazole exposure. Although the label appreciates that patients with *2, *3 CYP2C19 allelic variants have 4-fold higher exposure than the ones with wildtype *1 allele, no such information is shown for the patients harboring the *17 CYP2C19 allelic variant. Furthermore, no specific dose adjustment for CYP2C19 polymorphisms has been proposed. Clinical Pharmacogenomics Implementation Consortium (CPIC) guidelines 13 for voriconazole acknowledge that the PTA at labelrecommended voriconazole dose is very small and therapy should be avoided in UM and RM patients. The risk of treatment failure due to subtherapeutic drug exposure or toxicities associated with elevated drug exposure is mitigated via TDM in clinical practice.
14,15 However, TDM-based dose optimization approaches are perceived as being reliant to steady-state PK measures. Given the long half-life of voriconazole, establishment of PK steady-state typically takes 5-7 days, which can be detrimental to critically ill patients, 2 and is in fact unnecessary. One way of addressing this challenge is to complement TDM with model-informed approaches [16] [17] [18] in order to maximize the probability of achieving therapeutic steady state quickly. A major advantage of this combined approach is that it allows for prospective consideration of other clinically relevant sources of variability, such as CYP2C19 phenotype, drug-drug interactions, and the infecting organisms' susceptibility to voriconazole compared to retrospective dose adjustment using TDM only.
Our analysis revealed that the label-recommended 200 mg voriconazole dose would be sufficient to achieve the probability of target attainment for all phenotypes against Candida spp. infections. For less susceptible Aspergillus spp. infections, doses >200 mg were needed to achieve therapeutic concentrations in different clinical phenotypes. Voriconazole dose increase is also significantly associated with transient and reversible adverse events, such as VAE, followed by AST, ALP, and bilirubin elevation in patients. [19] [20] [21] As expected, RM/UM nonpantoprazole patients were at most risk for therapeutic failure of voriconazole. A voriconazole dose of 500 mg b.i.d. provided an optimal tradeoff between efficacy and safety for RM/UM nonpantoprazole patients, for treatment of A. fumigatus infections (Figure 3) . However, higher doses of 600, 550, and 600 mg were needed to maximize the net benefit for RM/UM nonpantoprazole patients, suffering from less sensitive infections such as A. flavus, A. niger, and A. terreus. For NM/IM nonpantoprazole and RM/UM pantoprazole patients, doses of 400 mg and 450 mg were found to be sufficient for treatment of A. niger/A. fumigatus and A. terreus/ A. flavus infections, respectively. In NM/IM pantoprazole patients, doses ranging from 300-400 mg were predicted to be effective, depending on the type of infection. At proposed doses, the probability of bilirubin elevation only increases by 5% compared to the label-recommended 200 mg dose, not found to be critical for dose selection. It is also important to note that voriconazole use is associated with other CNS toxicities besides VAE, such as headache, confusion, hallucination, dizziness, euphoria, amnesia, etc. However, the frequency of these adverse events is <2% in patients 4 and not considered dose-limiting. 22 Furthermore, projected doses are in line with a retrospective study, 23 which found that a 4 mg/kg (280 mg for a 70 kg adult) and 6.75 mg/kg (475 mg for a 70 kg adult) voriconazole dose was required to achieve target concentrations in CYP2C19 RM and UM phenotypes, respectively. In our study, statistical distinction of RM and UM were not possible, due to very small number of patients in the UM group (N 5 4) . Given the reversible nature of adverse events associated with voriconazole, as opposed to the detrimental effects of treatment failure, benefits associated with dose escalation may outweigh the risks in the long term. 24 It should also be acknowledged that the impact of CYP2C19 RM/UM phenotype on the voriconazole pharmacokinetics [25] [26] [27] has not been studied extensively. To the authors' knowledge, this is the first study that has quantified the changes in steady-state clearance of voriconazole due to *17 CYP2C19 genotype as well as pantoprazole use and translated those findings into an optimal dose recommendation. Based on in vitro findings pantoprazole is a weak inhibitor of CYP2C19 compared to other proton pump inhibitors (PPI), such as omeprazole. 28 However, in vivo studies [29] [30] [31] show that pantoprazole use can lead to a significant increase in C trough,ss of voriconazole. Moreover, benefits from TDM of voriconazole were greater in the patients who were cotreated with PPI at dosages 40 mg intravenously. 29 Our results are in line with these literature reports and show that pantoprazole use significantly increases the PTA in both NM/IM and RM/UM phenotypes due to increased voriconazole exposure.
Studies have also shown that the PK of voriconazole can be influenced by concomitant administration of CYP3A4 inhibitors 33 For example, Mikus et al. 32 showed that the coadministration of a potent CYP3A4 inhibitor can lead to a higher and prolonged exposure of voriconazole, which in turn can increase the risk of experiencing adverse drug reactions, particularly in CYP2C19 PMs. The results of our study are inconclusive in this regard because none of the study subjects were taking a CYP3A4 inhibitor or inducer during treatment with voriconazole. Furthermore, our clinical study had only one CYP2C19 PM patient, which was excluded from the modeling analysis as it was not feasible to estimate a covariate effect on clearance using data from only one subject. Our current model consequently does not provide dosing recommendations for CYP2C19 PMs but can be readily updated as additional clinical data become available.
For voriconazole, different PK/PD indices have been used as predictors of clinical efficacy. In a neutropenic murine model of disseminated candidiasis, 34 fAUC 24 /MIC correlated well with the clinical efficacy of voriconazole. However, the predictive performance of this PK/PD index has not been confirmed in human studies. In clinical practice, C trough,ss provides a more robust and easier to obtain measure than AUC and is consequently used for dose adjustment. Attainment of C trough,ss values as low as 1 mg/L (C trough,ss >1) 35 and as high as 2 mg/L (C trough,ss >2) [36] [37] [38] were found to correlate with clinical efficacy. Literature evidence suggests that underexposure is associated with poor outcomes. For example, Pascual et al. 35 showed that a significantly higher proportion of patients with levels 1 mg/L received oral voriconazole. Lack of response to therapy was more frequently observed in patients with levels 1 mg/L (46%) than in those with levels >1 mg/L (12%; P 5 0.02). Evidence from an observational study 39 further suggests that consideration of the pathogen's MIC along with C trough,ss , i.e., C trough,ss /MIC >2, correlates well with efficacy, and hence has been proposed as a suitable PK/PD index of efficacy for voriconazole. Our findings show that both fAUC 24 /MIC and C trough,ss /MIC >2 result in similar probabilities of target attainment (Figure 1a,b) . It should be noted, however, that probabilities associated with C trough,ss >2 index ( Table 1) will not be identical with those derived from fAUC 24 /MIC and C trough,ss /MIC >2 indices using MIC values different from 1 mg/L. Dose optimization based on C trough,ss >2 may not be optimal for pathogens with MIC less than or greater than 1, since it does not account for susceptibility of infection. Hence, the choice of using human-data driven and MIC-based PK/PD index, i.e., C trough,ss /MIC >2 over an animal model-derived index, i.e., fAUC 24 /MIC and non-MIC-based index, i.e., C trough,ss >2 for dose optimization is well justified.
Our analysis indicates that a label-recommended dose of 200 mg voriconazole would be optimal for all phenotypic groups of patients in case of Candida spp. infections; however, dose should be adjusted based on patients' phenotype in the case of Aspergillus spp. infections. Ideally, the proposed dosing recommendations should be validated in a prospective clinical study by comparison with the TDM-based approach. Linkage of a developed PK/PD model with clinical outcomes (treatment success or failure) database can also provide valuable insights in the predictive utility of a proposed approach. It could also be argued that TDM can provide the same answer; however, with a delay of 5-7 days. With rapid development of point-of-care (PCT) CYP2C19 genotyping assays, the time needed to genotype patients can be reduced and proposed dose adjustments can help in achieving target exposure, much earlier in the treatment time course. However, CYP2C19 genotyping/susceptibility testing may not always be feasible in all clinical settings. Isavuconazole or posaconazole, which do not undergo metabolism via CYP2C19, can be considered as potential alternatives in those cases. 13 The findings of this study are limited by the lack of MIC data in our patients and comparatively small sample size (n 5 69). For these two reasons, this study could not delineate an exposureoutcome relationship, also in view of the impact of patient genotype and comedication(s). To address this limitation and establish an exposure-outcome relationship, MIC data should be collected in future clinical trials.
In conclusion, TDM-directed and genotype-directed are not mutually exclusive dose optimization approaches, but rather informative of one another. Our analysis evaluates the advantages and limitations of the two in light of voriconazole's PK, associated variability due to CYP2C19 polymorphisms and comedications, the infecting pathogen's susceptibility, as well as the prospective or retrospective use of the drug. It also shows that knowledge of the susceptibility of the infecting organism is key for successful antifungal therapy.
METHODS Patients and data collection
We previously conducted a clinical study 8 to prospectively evaluate the impact of CYP2C19 polymorphisms on the PK of voriconazole (N 5 70) in patients receiving weight-based dosing. Respective patient demographics and clinically relevant patient characteristics are listed in Table 2 . The majority of the patients were Caucasians (80.9%) who also received pantoprazole (70.6%). Steady-state PK data were available in 68 patients (27 NM, 14 IM, 3 RM, and 24 UM), excluding one NM patient with unphysiological peak concentration (due to a sample collection error) i.e., C peak,ss (39 mg/L), and one poor metabolizer (*2/*2). Exploratory analysis from the previous study 8 highlighted the significant interindividual variability in C trough,ss (range 5 0.26-9.53 mg/L), indicating the involvement of potential covariates (Figure 5a ). Median C trough,ss were lower in RM/UM group (median 5 1.9, 90% confidence interval (CI) 5 0.3-6.6 mg/L) compared with that of NM (median 5 4.6, 90% CI 5 0.5-7.2 mg/L) and IM (median 5 4.7, 90% CI 5 1.7-6.1 mg/L) groups at the same mg/kg voriconazole dose (Figure 5b) . Interestingly, there was a considerable overlap between the 90% CIs of RM/UM, NM, and IM groups, indicating other potential sources of variability. Additionally, patients who were taking pantoprazole had higher median C trough,ss (median 5 4.5, 90% CI 5 0.5-7.2 mg/L) in comparison with patients who were not (median 5 1.9, 90% CI 5 0.3-4.9 mg/L) ( Figure 5c) . However, the association between genotype and trough concentrations remained after accounting for pantoprazole use. This is consistent with the fact that pantoprazole competitively inhibits CYP2C19, resulting in higher voriconazole concentrations.
Population PK analysis C peak,ss and C trough,ss data obtained from our previous clinical study 8 was characterized using nonlinear mixed effect modeling in NONMEM v. 7.3. One-and two-compartment models with nonlinear elimination were tested as structural models using first-order conditional estimation method with interaction. Additional details on the structural-, variance-, and covariate model are provided as Supplementary Material. The model's performance was evaluated based on the goodness of fit plots and nonparametric bootstrapping method (Supplementary Information).
Population PK/PD analysis Once developed, the PopPK model was linked to MIC distribution data in NONMEM v. 7.3 to perform 2c000 Monte Carlo Simulations (MCS) 40 following label-recommended dosing regimen of voriconazole (400 mg b.i.d. orally for 24 h, 200 mg b.i.d. orally thereafter). C trough,ss were determined and the probability of target attainment (PTA) were calculated (details in Supplementary) for different preclinical and clinical PK/PD indices of efficacy for voriconazole: 1) PTA1-Probability of achieving C trough,ss >2 mg/L (clinical), 8 the most commonly used index; 2) PTA2-Probability of achieving fAUC 24 /MIC 25 (preclinical) 34 ; 3) PTA3-Probability of achieving C trough,ss /MIC >2 (clinical). 39 MCS results were also expressed in terms of cumulative fraction of response (CFR), defined as "the expected population probability of target attainment for a specific drug dose and a specific population of microorganisms" 41 (see Equation 9 in the Supplementary Information). Due to the unavailability of MIC data in our previous study, 8 we used the MIC distributions for four Aspergillus spp. (A. fumigatus, A. niger, A. terreus, A. flavus) and 11 Candida spp. (C. albicans, C. dubliniensis, C. famata, C. glabrata, C. guilliermondii, C. kefyr, C. krusei, C. lusitaniae, C. parapsilosis, C. pintolopesii, C. tropicalis) from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) database 42 for our computations (Figure 5d ). PTA and CFR were calculated for the label-recommended maintenance dose of voriconazole (200 mg b.i.d. orally) as well as higher maintenance doses of voriconazole, i.e., 250, 300, 350, 400, 450, 500, 550, and 600 mg b.i.d. orally. In addition, we computed the probabilities of experiencing adverse events, such as visual adverse event (VAE) and hepatotoxicity (aspartate transaminase (AST) elevation, alkaline phosphatase (ALP) elevation, and bilirubin elevation) for these dosing regimens using published relationships. 19 A benefit-risk analysis was conducted and optimal doses of voriconazole were selected based on the maximal difference (net benefit) between benefit and risk.
Net benefit 5 Probability of benefit -Probability of risk (VAE/ hepatotoxicity) Additional Supporting Information may be found in the online version of this article. 
